Related Experiment Video
Updated: Feb 7, 2026

Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
GDC-0084 inhibits cutaneous squamous cell carcinoma cell growth
Ling-Tao Ding1, Peng Zhao2, Min-Lie Yang2
1Department of Plastic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China; Department of Burns and Plastic Surgery, The Third Affiliated Hospital of Nantong University, Wuxi, Jiangsu, China.
Abstract:
GDC-0084 is a novel and potent small-molecule PI3K-mTOR dual inhibitor. The present study examined its potential activity in cutaneous squamous cell carcinoma (cSCC) cells. Our results show that GDC-0084 treatment at nanomole concentrations potently inhibited survival and proliferation of established (A431, SCC-13 and SCL-1 lines) and primary human cSCC cells. GDC-0084 induced apoptosis activation and cell cycle arrest in the cSCC cells. It was more efficient than other known PI3K-Akt-mTOR inhibitors in killing cSCC cells, but was non-cytotoxic to the normal human skin fibroblasts/keratinocytes. In A431 cells and primary cSCC cells, GDC-0084 blocked phosphorylation of key PI3K-Akt-mTOR components, including p85, Akt, S6K1 and S6. GDC-0084 also inhibited DNA-PKcs activation in cSCC cells. Significantly, restoring DNA-PKcs activation by a constitutively active-DNA-PKcs (S2056D) partially inhibited GDC-0084-induced cell death and apoptosis in A431 cells. In vivo, GDC-0084 daily gavage potently inhibited A431 xenograft tumor growth in mice. In GDC-0084-treated tumor tissues PI3K-Akt-mTOR and DNA-PKcs activation were significantly inhibited. In summary, GDC-0084 inhibits human cSCC cell growth in vitro and in vivo through blocking PI3K-Akt-mTOR and DNA-PKcs signalings.
Insights
GDC-0084, a PI3K-mTOR dual inhibitor, effectively suppressed cutaneous squamous cell carcinoma (cSCC) cell growth and proliferation in vitro and in vivo. This novel compound demonstrated potent anti-tumor activity by inhibiting key signaling pathways without harming normal skin cells.
Area of Science:
- Oncology
- Molecular Biology
- Dermatology
Background:
- Cutaneous squamous cell carcinoma (cSCC) is a common skin cancer.
- Targeting the PI3K-Akt-mTOR pathway is a promising strategy for cancer treatment.
- Developing novel inhibitors with improved efficacy and selectivity is crucial.
Purpose of the Study:
- To evaluate the anti-cancer potential of GDC-0084, a novel PI3K-mTOR dual inhibitor, against cutaneous squamous cell carcinoma (cSCC).
- To investigate the molecular mechanisms underlying GDC-0084's activity in cSCC cells.
- To assess the in vivo efficacy of GDC-0084 in a preclinical model of cSCC.
Main Methods:
- Treatment of established and primary human cSCC cells with GDC-0084.
- Assessment of cell survival, proliferation, apoptosis, and cell cycle arrest.
- Analysis of key signaling pathway components (PI3K-Akt-mTOR, DNA-PKcs) phosphorylation.
- Evaluation of GDC-0084 efficacy in a murine xenograft model of cSCC.
Main Results:
- GDC-0084 potently inhibited cSCC cell survival and proliferation at nanomolar concentrations.
- GDC-0084 induced apoptosis and cell cycle arrest in cSCC cells, showing greater efficiency than other inhibitors.
- GDC-0084 blocked PI3K-Akt-mTOR and DNA-PKcs signaling pathways in cSCC cells.
- GDC-0084 demonstrated significant anti-tumor activity in vivo, inhibiting xenograft growth and related signaling pathways.
Conclusions:
- GDC-0084 is a potent PI3K-mTOR dual inhibitor with significant anti-cancer activity against cSCC.
- GDC-0084 exerts its effects by inhibiting PI3K-Akt-mTOR and DNA-PKcs signaling pathways.
- GDC-0084 represents a promising therapeutic candidate for cutaneous squamous cell carcinoma treatment.
Related Concept Videos
Cells Coordinate Growth and Proliferation
Feedback Inhibition
Primary and Secondary Growth in Roots and Shoots
Enzyme Inhibition
Meristems and Plant Growth
Population Growth

